Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Saved in:
| Title: | Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. |
|---|---|
| Authors: | Yee AJ; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Laubach JP; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Campagnaro EL; Division of Hematology and Oncology, University of Michigan Cancer Center, Ann Arbor, MI., Lipe BC; Department of Hematology/Oncology, University of Rochester, Rochester, NY., Nadeem O; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Friedman RS; Newton-Wellesley Hospital, Newton, MA., Cole CE; Division of Hematology and Oncology, University of Michigan Cancer Center, Ann Arbor, MI., O'Donnell EK; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Bianchi G; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Branagan AR; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Schlossman RL; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Shapiro SJ; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Harrington CC; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Burke JN; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Gammon MT; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Lively KJ; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Reimonn CA; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Andrade DX; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Redd R; Dana-Farber Cancer Institute, Boston, MA., Lohr JG; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Anderson KC; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Richardson PG; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Raje NS; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA. |
| Source: | Blood advances [Blood Adv] 2025 Mar 11; Vol. 9 (5), pp. 1163-1170. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
